SWOG clinical trial number
S1900J

A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)

2% Accrual
Accrual
2%
Open
Phase
2% Accrual
Accrual
2%
Abbreviated Title
Targeted Treatment for Advanced NSCLC with High MET-Amplification
Status Notes
S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
Activated
09/27/2024
Participants
US INSTITUTIONS ONLY

Research committees

LungMAP

Treatment

Amivantamab SC (subcutaneous)

Reports & Approvals

Trial Locations